Novo Nordisk and Anthropic Announce Collaboration to Deploy Claude Science Inside R&D Workflows; Denmark's Largest Pharma Tests Frontier-Lab AI for Medicine Discovery and Development
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) and Anthropic announced Wednesday September 16, 2026 a collaboration to accelerate medicine development and strengthen the Danish pharma company's AI-driven software capabilities. Novo Nordisk will start by testing Claude Science, Anthropic's specialized research-workflow model line, inside specific research-and-development workflows including biology-focused literature synthesis, hypothesis generation, and internal knowledge management. Terms and financial structure of the collaboration were not disclosed. The deal makes Novo Nordisk one of the first large pharma companies to publicly commit to Claude Science deployment inside internal research workflows, following comparable Anthropic-plus-pharma tie-ups at other companies over the past twelve months. The Novo-Anthropic deal lands as Novo faces heightened investor pressure to demonstrate non-GLP-1 growth options and R&D productivity ahead of the September 21 Capital Markets Day in London — Morgan Stanley cut Novo Nordisk to Underweight on Friday September 11 citing the semaglutide patent-cliff exposure (approximately 75% of 2026 sales) and mid-term growth concerns. AI-drug-discovery tie-ups by themselves rarely move analyst models but can shift the pipeline-narrative arc.